(Total Views: 401)
Posted On: 01/06/2018 9:07:42 PM
Post# of 30066
Update on Amarantus Bioscience Holdings, Inc. Target Price: $0.65
Some may have just read the news but missed the link to the full report when it came out recently. It's a nice in depth look at all aspects of the company which would be a good start for new investors especially the peer group comps.
https://www.baystreet.ca/articles/research_re...-FINAL.pdf
Some may have just read the news but missed the link to the full report when it came out recently. It's a nice in depth look at all aspects of the company which would be a good start for new investors especially the peer group comps.
Quote:
Amarantus has disclosed a plan to move forward, restarting
company activities in January 2018 with an aim to monetize
its subsidiary companies through Reg A+ listings on
Nasdaq CM or NYSE American, beginning with Elto
Pharma, or other strategic transactions
https://www.baystreet.ca/articles/research_re...-FINAL.pdf
(8)
(0)
